Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore

CONCLUSION: Based on the common willingness-to-pay threshold of SGD 50,000/QALY, this study demonstrates the cost-effectiveness of WVTT over MM as first-line treatment for patients with moderate or severe BPH, suggesting it represents good value for money and should be considered for subsidy. PUL is not cost-effective as first- nor second-line treatment. For patients with severe BPH, TURP as first-line is also cost-effective.PMID:37800562 | DOI:10.1080/13696998.2023.2266958

Source: Journal of Medical Economics - October 6, 2023 Category: Health Management Authors: Junxing Chay Joshua Yi Min Tung Rebecca Jade Su Edwin Jonathan Aslim Callix Wong Georgia Swan Wei Jin Chua Henry Sun Sien Ho Eric Andrew Finkelstein Source Type: research